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Abstract
Background: In high-transmission areas, developing immunity to symptomatic Plasmodium falciparum
infections requires 2–10 years of uninterrupted exposure. Delayed malaria-immunity has been attributed
to difficult-to-develop and then short-lived antibody responses.
Methods: In a study area with <0.5 P. falciparum infections/person/year, antibody responses to the MSP1-
19kD antigen were evaluated and associations with P. falciparum infections in children and adults. In months
surrounding and during the malaria seasons of 2003–2004, 1,772 participants received ≥6 active visits in
one study-year. Community-wide surveys were conducted at the beginning and end of each malaria
season, and weekly active visits were completed for randomly-selected individuals each month. There
were 79 P. falciparum infections with serum samples collected during and approximately one month before
and after infection. Anti-MSP1-19kD IgG levels were measured by ELISA.
Results: The infection prevalence during February-July was similar in children (0.02–0.12 infections/
person/month) and adults (0.03–0.14 infections/person/month) and was negligible in the four-month dry
season. In children and adults, the seroprevalence was maintained in the beginning (children = 28.9%, adults
= 61.8%) versus ending malaria-season community survey (children = 26.7%, adults = 64.6%). Despite the
four-month non-transmission season, the IgG levels in Plasmodium-negative adults were similar to P.
falciparum-positive adults. Although children frequently responded upon infection, the transition from a
negative/low level before infection to a high level during/after infection was slower in children. Adults and
children IgG-positive before infection had reduced symptoms and parasite density.
Conclusion: Individuals in low transmission areas can rapidly develop and maintain αMSP1-19kD IgG
responses for >4 months, unlike responses reported in high transmission study areas. A greater immune
capacity might contribute to the frequent asymptomatic P. falciparum infections in this Peruvian population.
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Background
The prospect of decreasing millions of Plasmodium falci-
parum  malaria deaths each year [1,2] hinges upon the
development, implementation and evaluation of vac-
cines. A successful strategy requires an appreciation of the
human-host immune response development upon natu-
ral infection. Longitudinal studies in hyperendemic
malaria transmission areas have elucidated factors related
to the development – or lack of development – of anti-
body responses [3-10]. Due to overlapping malaria infec-
tions in high transmission areas, where infections occur
monthly or even daily, it is difficult to study the immuno-
logical responses elicited upon and maintained after a dis-
crete infection. Additionally, studies in high transmission
areas have a limited ability to consider age because partic-
ipants suffer many infections during their first five years of
life [11].
For such reasons, the Peruvian Amazon, a recent and low
malaria transmission region, offers unique research
opportunities. P. falciparum emerged in this area in 1994,
and fewer than 0.42 infections/person/year (with trans-
mission occurring seven months out of the year) have
been detected since 2000, even when using active case
detection (ACD) in the most at-risk age groups (12–30
years old) living in the highest transmission zones [12].
Despite this low and recent transmission, there is an
abundance of non-febrile infections [12,13]. A 2005 study
of 72 infections demonstrated that 45 of these infections
remained asymptomatic, with no indication of fever,
anaemia, or parasitaemia greater than 5,000 parasites/μl
of blood for one week[12]. Surprisingly, 15 of these 45
asymptomatic individuals were P. falciparum-negative one
week later, were not treated, and remained without micro-
scopy-detectable P. falciparum parasites for at least one
month [12].
In the current study, the antibody responses to the 19kD
fragment of P. falciparum Merozoite Surface Protein-1
(MSP1-19kD) are characterized. MSP1-19kD is one of the
most well studied malaria vaccine candidates. Experimen-
tal infection studies and in vitro and animal model studies
have demonstrated an association between αMSP1-19kD
antibodies and protection from clinical infection [5,14-
18]. The protective effects of antibodies to MSP1-19kD are
postulated to occur by inhibiting the proteolytic cleavage
of MSP-1 needed to expose the 19kD fragment and/or by
blocking the MSP1-19kD from binding to erythrocytes.
Immuno-epidemiologic studies suggest that αMSP1-
19kD IgG responses are associated with reduced clinical
symptoms, reduced parasitemia, and reduced risk of sub-
sequent infection [4,5,7,9,19]. However, the fact that
immunity does not develop until years after exposure to
this highly conserved antigen brings the vaccine candi-
dacy of MSP1-19kD into question. In fact, although pos-
sibly explained by a myriad of factors, a recent clinical
vaccine trial using a 42kD fragment of MSP1 (19kD along
with MSP1's upstream 33kD fragment) was not signifi-
cantly associated with protection.
This investigation was prompted by prior studies in high
transmission regions that suggested a slow or difficult-to-
develop αMSP1-19kD response (requiring high parasitae-
mia and/or frequent infection) which, when developed, is
short-lived, lasting less than six months[3,6,7,10], even in
individuals >5 years old[3,4,6,7,10,21,22]. Therefore it
was predicted that αMSP1-19kD responses in Peruvian
individuals would be infrequent or absent before each
widely-spaced infection. On the contrary, this study sug-
gests that this population has a high capacity for eliciting
and maintaining αMSP1-19kD IgG responses. This
immune capacity may contribute to the high frequency of
asymptomatic  P. falciparum infections observed in this
Peruvian population [12,13].
Methods
Study area and participants
The Malaria Immunology and Genetics in the Amazon
(MIGIA) study takes place in a community called Zunga-
rococha (there are 1907 individuals enrolled in our study
from this community) with a maximum P. falciparum
infection rate of 0.42 infections/person/year (details in
Branch et al [12]).
In 2003 and 2004 active case detection (ACD) was under-
taken during the malaria transmission season (February –
July) and passive case detection (PCD) was performed
throughout the year. ACD was conducted in two different
ways. In three community-wide surveys as many commu-
nity members as possible were sampled using home-
based visits: March 2003 (N = 363), February 2004 (N =
1156), and August 2004 (N = 861). Additionally, each
month during malaria season (April-July 2003 and also
March-July 2004), approximately 220 community-mem-
bers were randomly selected from 100-meter regions sur-
rounding homes where P. falciparum was detected during
the prior month and were enrolled for one month of
weekly home-based visits. There were 1,722 participants
who completed at least four ACD visits in one malaria sea-
son: 671 in 2003 and 1051 in 2004, of which 423 com-
pleted at least four ACD visits both in 2003 and 2004.
Additionally, throughout 2003 and 2004 infections were
detected via PCD at the local health post. All individuals
entering the Zungarococha health post complaining of
febrile illness or other malaria-like symptoms had a blood
slide read by an expert microscopist. Malaria treatment is
free and tightly controlled (observed therapy), and there
is no access to private physicians.Malaria Journal 2008, 7:173 http://www.malariajournal.com/content/7/1/173
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At each ACD and PCD, a detailed clinical and epidemio-
logic evaluation was made by a trained physician and
blood was collected (0.25 ml in ACD and 3–6 ml in
PCD). Thin and thick blood-smears were made, haemat-
ocrit capillary tubes were filled, and blood was separated
into packed erythrocytes and sera and stored at -70°C.
Human subjects approval
All individuals in the community were invited to partici-
pate in the ACD study protocol and clinic protocol if they
were diagnosed with malaria either in ACD or PCD. Ethi-
cal clearance was received from the University of Alabama
at Birmingham, the Universidad Peruana Cayetano Here-
dia (Lima, Peru), and the Ministry of Health (MINSA,
Lima, Peru).
Diagnosis
Thick blood smears were examined using Giemsa staining
and oil-immersion microscopy by three highly qualified
microscopists. If >50 ring-stage parasites were detected
after reading 200 leukocytes, parasitaemia was calculated
from these fields. Otherwise, at least 500 leukocytes were
counted. Parasitaemia was expressed as the number of
parasites/μL of blood, assuming 6,000 leukocytes/μL. The
blood-smear was considered negative if no parasites were
seen in 200 fields.
Treatment
Whether in active or passive case detection, all treatments
were given through the MINSA authorities, following the
MINSA National Drug Policy Guidelines. Plasmodium
vivax treatment is chloroquine (10 mg/kg for three days)
with primaquine (0.5 mg/kg for seven days). Plasmodium
falciparum treatment is mefloquine (12.5 mg/kg daily for
two days) with artesunate (4 mg/kg daily for three days)
in non-pregnant patients older than one year of age.
Measurement of IgG
The recombinant P. falciparum MSP1-19kD, correspond-
ing to Ugandan-PA P. falciparum strain (with the MSP1-
19kD 4 aa variant positions of E-K-N-G)[23], was
expressed in Sacharomyces cerevisiae (provided by Dr.
David Kaslow). The variants E-K-N-G and Q-K-N-G are
the only P. falciparum MSP1-19kD detected in this popu-
lation. One hundred and twenty eight randomly selected
samples were tested (by ELISA). The anti-EKNG and anti-
QKNG IgG responses (Negative/Low Positive/High Posi-
tive) were nearly identical (concordance = 92%).
An enzyme-linked-immunoabsorbent assay (ELISA) for
total IgG was performed as described previously [7].
Briefly, plates (Dynatech) were coated with 50 μL/well of
recombinant MSP1-19kD (at a concentration of 0.5 ng/
μL) and blocked with 1% bovine serum albumin (BSA).
The sera were diluted 1:100 (1.5% non-fat milk in wash-
ing-solution [0.15 M Na2HPO4, 0.15 M NaH2PO4, NaCl,
0.05% Tween20, and 0.05% BSA]). The IgG that bound to
the MSP1-19kD on the plate were detected with peroxi-
dase-conjugated goat-antihuman-IgG (Chemicon)
diluted 1:2000. The plates were washed, 50 μL/well of
3,3',5,5'-tetramethylbenzidine (KPL) was added, the reac-
tion was stopped using 50 μL/well of 0.25 M HCL, and
then read at absorbance 450 nm (A450) with an ELISA
plate-reader (BIORAD).
Ten serum samples from healthy non-exposed Peruvians
were used as negative controls. The positive controls
included five samples from five different P.falciparum-
infected individuals and a "positive pool" made-up of
three samples.
A positive pool control standard-curve was made for each
experiment day. The positive pool was diluted at 1:50,
1:100, 1:400, 1:1600, 1:3200, and 1:12800. The results
from each day showed similar curves. The average positive
pool optical density (OD) at a 1:400 dilution for all exper-
iment days was subtracted from the positive pool OD for
each individual experiment day. The resulting correction
factor was subtracted from the initial OD of each sample,
thereby standardizing by experiment day.
Samples with an OD greater than the negative cutoff (the
average of the negative controls plus 2 standard devia-
tions) were considered positive. The positive group was
divided into "Low" and "High," where an OD greater than
3 times the negative cutoff was called "High-Positive."
Study design and statistical analysis
Of 1,722 individuals, 600 individuals were selected who
participated in at least one ACD community survey: 300
children (1–14.5 years-old) and 300 adults (14.6–104
years-old). Of these 600 age-grouped and then randomly
selected individuals, 448 participated in 2 of the 3 com-
munity surveys, and 49 participated in all three commu-
nity surveys. There were a total of 868 sample-events in
the three community surveys.
Seventy-nine P. falciparum infections (from 79 different
individuals) were selected from the 182 infections
detected in ACD because these represented individuals
who had sera samples available from before, during, and
after their infection. Forty-one of these were adult infec-
tion samples.
"Before", "During", and "After" infection time points were
selected. From samples collected within 3 months before
infection, the sample closest to 1 month before was
selected as "Before": median days until infection (1st–3rd
quartile) = 38 days (14–68). From samples collected
within 3 months after infection, the sample closest to 1Malaria Journal 2008, 7:173 http://www.malariajournal.com/content/7/1/173
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month after was selected as "After": 22 days (14–53). The
before, during, and after sera samples were encountered
for 79 individual infections.
An infection was classified as "symptomatic" if the indi-
vidual had a fever greater than or equal to 38.3°C,
reported a fever in the past 2 days, or had a haematocrit of
less than 30 PCV either at the time of or within one week
after infection.
Statistical analysis was conducted using SAS (SAS Cary,
NC, version 9). Chi square (χ2) analysis tested infection
and seroprevalence differences. A non-parametric Wil-
coxon Rank Sums (WRS) tested antibody level differences.
A general linear model (GLM with General Estimating
Equations (GEE) obtained by SAS procedure "GEN-
MOD") determined variables associated with antibody
level changes upon infection. The independent variables
considered were age, logarithmic parasite density, sex and
days separating the measurements of IgG. The GLM
dependent variable was the IgG OD "During" minus the
IgG OD "Before" time point. When testing frequency of
fever with antibody response description over time
(response profile), a Fisher's Exact and Mantel-Haenszel
Chi-Square was used. Logistic regression analysis (also
using GENMOD) determined if the above-listed variables
could predict symptomatic infections, using risk estimates
calculated by the GEE.
Results
Plasmodium falciparum prevalence and αMSP1-19kD 
IgG seroprevalence in three community surveys
Infection prevalence (Figure 1) was calculated during the
ACD community surveys (point prevalence) and also dur-
ing the month of weekly ACD (monthly prevalence) for
each individual. Each month, adults usually demon-
strated a higher frequency of infection than children (Fig-
ure 1); however, this was not significantly different (χ2, p
= 0.0901). The study-period PCD data as well as the his-
toric records and the entomologic data [12,24] agree that
malaria infections rarely occur within the dry season of
August through December. In addition, during a recent
small community survey that was conducted specifically
to verify that there is negligible transmission during the
dry season, 238 blood samples were collected in Novem-
ber through December, 2007. This survey included 123
febrile individuals as well as 115 non-febrile family mem-
bers who simply accompanied the febrile individual to
the community health center (sampling these individuals
fell within the same ethically-reviewed protocol as
described in this manuscript). Of these 238 individuals,
all were microscopy negative for malaria and only one was
PCR (sub-microscopy) positive for P. vivax. None were
PCR positive for P. falciparum.
Returning to our 2003–2004 data, as expected due to the
dry season beginning in July, the infection prevalence was
near zero in the August 2004 community survey (Figure
1). Even though there was a similar infection prevalence
in adults and children, significantly fewer children were
IgG positive, regardless of the community survey epoch,
versus adults (χ2, p < 0.05 for each community survey, Fig-
ure 1). For example, in the 2003 malaria season commu-
nity survey (March 2003), 34.8% of children and 76.8%
of adults were IgG-positive (point seroprevalence).
Despite low transmission, the αMSP1-19kD seropreva-
lence in the beginning versus the end of the transmission
season was similar (Figure 1). Although it is possible that
some individuals had a malaria infection on or before the
February 2004 survey, only a small proportion of the
αMSP1-19kD positivity could be attributable to such a
rare early-season malaria infection given the low transmis-
sion. Specifically, given the maximum P. falciparum trans-
mission rate found in ACD and PCD, together, in the
highest transmission zones of this community [12], the
probability of infection during the 4 months between
these two community surveys was only 0.06.
αMSP1-19kD IgG responses are maintained
In both Plasmodium-negative adults and children, the fre-
quency of having a High Positive IgG response varied by
<5% between the community survey conducted at the
beginning of the 2004 malaria season (February 2004)
and that conducted at the end of the 2004 malaria season
(August 2004) (χ2, p < 0.05; Table 1).
Several Plasmodium-negative individuals in the February
2004 survey were infected with P. falciparum at some time
during the following malaria season. One-hundred and
thirty-five individuals were evaluated who were Plasmo-
dium-negative in February 2004 and also who were in
both the February 2004 and the August 2004 community
surveys (e.g., represented twice in Table 2). Seven of the
29 individuals who were IgG negative in February 2004
were infected between March and July, 2004. In August
2004, five of these recently (but not currently) infected
individuals were αMSP1-19kD IgG positive. The only two
individuals who were IgG negative, despite this recent
infection, were children.
Similarly, Plasmodium-negative adults, but not children,
had high median αMSP1-19kD levels (1.040 versus
0.301; Table 2). The P. falciparum-infected adult median
αMSP1-19kD IgG level was not significantly different
than that seen in Plasmodium-negative adults, and the
majority of Plasmodium-negative adults had a high
αMSP1-19kD IgG level (3rd quartile = 0.505). The median
IgG level in P.falciparum-infected children (1.339) was
also similar to that seen in infected adults (Table 2).Malaria Journal 2008, 7:173 http://www.malariajournal.com/content/7/1/173
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Although most Plasmodium-negative children had low
αMSP1-19kD IgG levels, some had a high αMSP1-19kD
IgG level (3rd quartile = 0.827).
The αMSP1-19kD IgG level in P. vivax-infected individu-
als (detected in community surveys) was similar to that in
Plasmodium-infected children (Table 2). The low homol-
ogy between the P. vivax and P. falciparum MSP1-19kD
[25] supports this observation.
Age-related IgG dynamics before, during and after 
infection
Sera samples taken 'During' as well as approximately one
month 'Before' and one month 'After' infection were eval-
uated to determine the dynamics of the αMSP1-19kD IgG
antibody response and to see how this response changes
between age groups (Figure 2). A positive αMSP1-19kD
IgG response in the Before sample was observed in 36%,
69%, 84% and 85% of the 0–6, 7–14, 15–30, and >30
years-olds, respectively. In the 0–6 year-old group, the
median  αMSP1-19kD IgG was only 0.216 Before, but
0.712 During and then 1.08 After infection. Only the 0–6
year-old group had an increase in median αMSP1-19kD
level after infection. The Before IgG level clearly increased
with age. In the older age groups, there was little differ-
ence in median IgG level across During and After time
points.
The antibody level change upon detection of an infection
(which was predicted to be early in the infection due to
P. falciparum incidence and αMSP1-19kD prevalence in our study area between 2003–2004 Figure 1
P. falciparum incidence and αMSP1-19kD prevalence in our study area between 2003–2004. αMSP1-19kD IgG 
seroprevalence during March 2003, and February and August 2004, active case detection community surveys (bars) as well as P. 
falciparum point-prevalence during community surveys (open symbols) and weekly ACD conducted on sentinel individuals 
April-July, 2003, and March-July, 2004 (closed symbols, lines), and P. falciparum incidence in passive case detection (PCD) are 
shown (closed circles).
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Mar-03
Apr-03
May-03
Jun-03
Jul-03
Aug-03
Sept-03
Oct-03
Nov-03
Dec-03
Jan-04
Feb-04
Mar-04
Apr-04
May-04
Jun-04
Jul-04
Aug-04
0%
1%
2%
3%
4%
5%
6%
7%
8%
9%
10%
11%
12%
13%
14%
Children, anti-MSP-1 19KD Positive in ACD Adults, anti-MSP-1 19KD Positive in ACD
Children, PF prevalence in ACD Adults, PF prevalence in ACD
PF incidence in PCD
%
 
w
i
t
h
 
P
F
 
i
n
f
e
c
t
i
o
n
 
(
s
y
m
b
o
l
s
,
 
l
i
n
e
s
)
%
 
a
n
t
i
-
M
S
P
-
1
 
1
9
K
D
 
P
o
s
i
t
i
v
e
 
(
b
a
r
s
)Malaria Journal 2008, 7:173 http://www.malariajournal.com/content/7/1/173
Page 6 of 11
(page number not for citation purposes)
our ACD) was evaluated by subtracting the Before from
the During infection IgG OD in each individual (Figure
2). A step-down multivariate model of During-minus-
Before showed that each age-group of individuals >6
years-old had a significantly greater αMSP1-19kD level
change upon infection versus the 0–6 year-olds (GEE, p <
0.0418). None of the other variables tested (see methods)
were associated with this detection-associated change in
αMSP1-19kD level (p > 0.1).
Response profile associated with fever and parasite 
density
The αMSP1-19kD response profile was defined for each
individual infection by the responses measured in the
Before, During, and After infection samples as follows:
Pre-Positive
An individual who was High Positive at all three time
points or who was Low Positive Before infection and then
became High Positive After infection.
Infection Positive
An individual who was IgG negative Before infection but
then became High or Low Positive During and After infec-
tion.
Late Positive
An individual who was IgG negative Before and During
infection, but then became High or Low Positive After the
infection.
Non-Responder
An individual who did not have an antibody response at
all or was only Low Positive during the infection and then
became Negative after the infection.
Seventy-seven infections with complete clinical data
could be classified via these groupings (Table 3).
As shown in Table 3, the majority of adults were Pre-Pos-
itive (48.9%), while the majority of children were Infec-
tion Positive (48.5%). Fever was more frequent in
children (58.1%) versus adults (26.1%) (Fisher's Exact
Test, p = 0.0056). The geometric mean parasite density
(GMP [95% confidence interval]) was higher in children
than in adults (133 [218–509] versus 114 [71–185], WRS
p = 0.0050). Within each age group, the response profile
was associated with febrile illness (Mantel-Haenszel χ2, p
= 0.0048 in adults and p = 0.0212 in children), where Pre-
Positive had the lowest febrile frequency. Because the
number of adults in each IgG response profile category
was clearly different than children, multivariable logistic
Table 1: αMSP1-19kD by age group. In Plasmodium-negativea individuals, αMSP1-19kD IgG responsesb differed by age groupc, but were 
similar within age group at the beginning versus end of the malaria seasond.
Malaria status Age group Anti-MSP-1 19KD IgG response stratification Mar., 2003
(%, n)
Feb., 2004
(%, n)
Aug., 2004
(%, n)
NEG Adults ≤ negative cut-off 16.2% 33 38.2% 68 35.4% 40
NEG Adults > negative cut-off, but < 3 times negative cut-off 20.6% 17 13.5% 24 21.2% 24
NEG Adults ≥ 3 times negative cut-off 63.2% 92 48.3% 86 43.4% 49
NEG Children ≤ negative cut-off 54.2% 107 71.1% 118 73.3% 77
NEG Children > negative cut-off, < 3 times negative cut-off 23.2% 17 10.8% 18 10.5% 11
NEG Children ≥ 3 times negative cut-off 22.6% 40 18.1% 30 16.2% 17
p (chisq): age group by IgG response < 0.0001 < 0.0001 < 0.0001
aMalaria negative (NEG) = no Plasmodium infection (neither P. falciparum nor P. vivax) detected by microscopy or PCR.
bAntibody response stratification: Negative ≤ negative cut-off; High-Positive ≥ 3 times negative cut-off; Low-Positive > Negative and < High-Positive.
cAdults = ≥ 14 years old.
dFebruary 2004 = beginning of transmission season. August 2004 = end of transmission season.
Table 2: Comparison of αMSP1-19kD IgG responses with malaria infection status during community surveys. 
Malaria status Age group N (n < neg cut-off, n > 3* neg cut-off) Median Lower quartile Upper quartile p (WRS test)
PF Adults 14 (1, 14) 1.446 1.141 1.851 0.3132
PF Children 14 (3, 8) 1.339 0.740 1.803
NEG Adults 433 (141, 227) 1.040 0.505 1.562 <0.0001
NEG Children 435 (302, 89) 0.301 0.161 0.827
In adults, P. falciparum infected, P. vivax infected, and Plasmodium-negative (NEG) individuals had similar αMSP1-19kD IgG OD levels. The low 
αMSP1-19kD response frequency in NEG children suggests that fewer children had prior P. falciparum infection which could explain the maintained 
αMSP1-19kD antibody response seen in adults.Malaria Journal 2008, 7:173 http://www.malariajournal.com/content/7/1/173
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regression analysis was performed to investigate risk of
febrile infection (presented below).
While including age, response profile, and parasite den-
sity, age group was no longer predictive of risk to sympto-
matic infection (GEE, p = 0.2415) and was removed from
the model. Comparing to the Non-Responder profile, Pre-
Positive, Infection Positive, and Late Positive each had an
estimated risk of -2.23 (SE = 0.94), -0.61 (SE = 0.95), and
0.61 (SE = 1.3), respectively. There was a significant
decrease in risk to symptomatic infection in Pre-Positive
individuals versus Non-Responders (GEE, p = 0.0174).
Independently, with each increase in log parasite density
there was increasing risk of 0.61 (SE = 0.20) (p = 0.0018).
In a model comparing to the Infection Positive profile,
Pre-Positive individuals had an estimated risk of -1.397
(SE = 0.62; p = 0.0239), after controlling for the increased
risk of febrile illness with increasing parasite density
(GEE, p = 0.0039).
Discussion
In a low and recent falciparum malaria transmission area
of the Peruvian Amazon, the P. falciparum infection prev-
alence as well as the αMSP1-19kD IgG seroprevalence
were measured during community surveys. In addition,
the dynamics of IgG responses before, during, and after P.
falciparum infections and how this is related to asympto-
matic infections were evaluated in both children and
adults.
Similar to historic data [12,26] reported since 2000, para-
site prevalence was found to be low during the 2003 and
αMSP1-19kD IgG level dynamics in 79 P. falciparum infections Figure 2
αMSP1-19kD IgG level dynamics in 79 P. falciparum infections. αMSP1-19kD IgG level dynamics in 79 P. falciparum 
infections: During, approximately one month Before and approximately one month After infection, are shown while grouping 
by age. The box-plot shows the median (symbols), first, and third quartile boundaries boxed off and data range (the whiskers 
are drawn not including the <3 outliers per group, although all data are included when calculating the median and quartiles).
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2004 transmission seasons. When using active as well as
passive case detection the maximum P. falciparum infec-
tion rate was only 0.42 infections/person/year[12]. How-
ever, a limitation of this study is that ACD was not
conducted during the four month dry season. The reason
for this was that passive case detection was done through-
out the year and that all previously collected historic clin-
ical and entomologic data showed negligible malaria
transmission during the dry season[12]. As mentioned
earlier, to remedy this issue, a small community survey of
238 individuals was conducted during the dry season of
2007. Not a single P. falciparum infection was found (as
determined by both microscopy and PCR).
Despite this low transmission, the αMSP1-19kD IgG sero-
prevalence was comparable in the beginning versus the
end of malaria transmission season in both children
(27%–30%) and adults (53%–65%). Furthermore, the
median αMSP1-19kD IgG level was very similar in Plasmo-
dium-negative and P. falciparum-positive adults. This is
likely attributable to infections suffered in months or
years in the past, suggesting that αMSP1-19kD IgG
responses are maintained in the majority of individuals.
It is clear that the αMSP1-19kD response in both children
and adults in this cohort can last longer than the 1–4
months consistently described in high transmission stud-
ies[3,6,7,9,10,22]. It is important to note that the pres-
ence of P. vivax transmission in this area [12] could not
explain these results. As shown in this study, and in other
results from this laboratory, the αMSP1-19kD IgG
responses were P. falciparum-specific.
Finding children at the end of the 4-month low transmis-
sion season with antibodies shows that some children had
antibody lasting more than 4 months. However, P. falci-
parum-negative children had a median αMSP1-19kD IgG
of 0.301, which was clearly lower than P. falciparum-posi-
tive children (1.34) or P. falciparum-positive adults (1.45).
This is consistent with an age-related increase in cumula-
tive life time prior P. falciparum infections.
The accumulation of P. falciparum infections with age in
Peru is unlike that in high transmission regions, where all
individuals likely have had many infections during their
first years of life. In high transmission regions the
observed antibody responses do not reflect classical
response dynamics described in immunology text-
books[27]. Instead, they are short-lived as though the pri-
mary response is reinitiated, and the antibody secreting
cells seem to quickly undergo cell death after each infec-
tion[3,7,10,28,29]. In contrast, it is expected that if immu-
nologic memory develops with exposure/age, older
individuals would have an IgG response before infection
and a more rapid increase in IgG level upon infection.
This is exactly what was detected when comparing the
Before, During, and After αMSP1-19kD responses with
age in our Peruvian cohort. Because sampling date was
not dependent upon individuals coming to the clinic, the
results indicate that children 0–6 years-old were slower to
increase antibody levels in comparison to adults. Again,
this is consistent with the probability of prior P. falciparum
infection(s).
However, the age-related differences in seroprevalence,
IgG level when one is P. falciparum negative, and response
dynamics upon infection are also consistent with chil-
dren's intrinsically lower capacity for eliciting and main-
taining antibody responses that continues until
approximately 12 years of age[30,31]. These less well-
maintained responses of children were suggested by their
seroprevalence being lower than that of adults despite
similar P. falciparum infection prevalences during this two
year study. In fact, of the seven individuals who were
repeatedly sampled in beginning (February 2004) and
ending (August 2004) malaria season community sur-
Table 3: Adult and child IgG response profile as compared with clinical data during longitudinal follow-up. 
IgG response profile 
category
# with clinical 
information 
complete
% in each response 
category
# with febrile 
illness
% with febrile 
illness
GMP (95% CI)
Adult Pre-Positive 22 48.9% 4 18.2% 19 (6–60)
Infection-Positive 18 40.0% 9 50.0% 78 (37–164)
Late-Positive 1 2.2% 0 0 16 n/a
Non-responder 4 8.9% 3 75.0% 156 (12–2027)
Child Pre-Positive 6 18.2% 1 16.7% 8 (1–53)
Infection-Positive 16 48.5% 12 75.0% 284 (121–669)
Late-Positive 4 12.1% 4 100.0% 1210 (754–1941)
Non-responder 7 21.2% 6 85.7% 120 (26–561)
Adult and child IgG response profile was compared with febrile illness (patient-reported history or measured by physician within one week of 
infection) and parasite density, where infections were detected during one of 4 weekly active sampling visits. A pre-positive response, most 
frequently observed in adults, was associated with less febrile illness (χ2, p = 0.0056) and lower parasite density (WRS, p = 0.0005).Malaria Journal 2008, 7:173 http://www.malariajournal.com/content/7/1/173
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veys, and who were IgG Negative in February 2004 but
became infected during the 2004 season, the only two
individuals who were not IgG positive in the August 2004
community survey were children.
Similarly, as concluded by Tongren et al. in 2006[32] and
Akpogheneta et al. in 2008[33], our studies have found
that age is associated with a maintained seroprevalence. In
this study's Peruvian cohort, during 2003 and 2004, the
parasite prevalence was approximately 1% [12]. In the 4
month dry season of The Gambia, Africa, αMSP1-19kD
IgG responses lasted less than 4 months in all age groups
tested and less than 2 months in children less than 5 years
old. In this Peruvian cohort, priorly infected children less
than 5 years old had antibody responses lasting greater
than 4 months while the response in priorly infected
adults appeared even more long-lived.
Although our IgG subclass analysis has not yet been com-
pleted, it is interesting to consider that if IgG subclass
switching predicts longer duration antibody production,
then the results of Tongren et al. suggest that both age and
transmission intensity at some threshold between 1% and
18% are associated with more IgG1 and theoretically
longer lived total αMSP1-19kD IgG antibody
responses[32]. Akpogheneta et al. reported subclass
responses to malaria antigens, although antigens other
than  αMSP1-19kD, and found that older individuals
(individuals likely having had more prior exposure his-
tory) had a more maintained IgG1 response[33]. Support-
ing this suggestion, a study of 0–2 year-olds in Kenya
found that children who received P. falciparum infections
later in life had higher levels of αMSP1-19kD IgG and an
IgG subclass ratio more associated with protection
(mostly IgG1 and IgG3; not IgG2 and IgG4)[34].
Furthermore, in our study clinical symptoms of malaria
were associated with a pre-infection antibody response
(Table 3). A Pre-Positive αMSP1-19kD IgG response was
associated with lower frequency of fever as well as a lower
parasite density, in both adults and children. This empha-
sis on the Before infection antibody response is similar to
prior studies demonstrating that the antibody response
one month before an infection is often the best predictor
of a sub-clinical, low density infection[7,33].
Whether related to age at first infection and/or the slow
accumulation of prior P. falciparum infections, it is clear
that the αMSP1-19kD response in both children and
adults in this cohort can last longer than the 1–4 months
consistently described in high transmission stud-
ies[3,6,7,9,10,22]. It is possible that this immune capacity
is specific to this population of Peruvians (host-specific
factors) or P. falciparum parasites (parasite-specific fac-
tors). Another possibility is that spaced infections in low
transmission areas prime the immune response in a man-
ner that is especially effective for developing anti-malaria
immunity. This more generalized hypothesis is supported
by the few studies of antibody responses comparing pop-
ulations in low transmission regions versus high transmis-
sion regions. A study from Brazil showed that individuals
living in areas of lower transmission had higher anti-P. fal-
ciparum  immune responses than a neighboring village
with higher P. falciparum transmission[21]. Similarly,
Mlambo et al were surprised to find higher IgG levels in
populations living in low transmission regions versus
those in higher transmission for 3 (including MSP1-
19kD) of 5 vaccine candidate antigens tested[22].
In conclusion, despite the short-lived responses observed
in high transmission studies, at least in some populations
(such as our low transmission Peruvian cohort) it is pos-
sible to naturally acquire a maintained, clinically relevant
antibody response against P. falciparum, which is an
encouraging sign for all malaria vaccine initiatives.
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